Pathogenesis and management of arterial thrombosis
Willem L Bor
Department of Cardiology and Heart Center, St Antonius Hospital, Nieuwegein, the Netherlands
Search for more papers by this authorDean RPP Chan Pin Yin
Department of Cardiology and Heart Center, St Antonius Hospital, Nieuwegein, the Netherlands
Search for more papers by this authorJurriën M ten Berg
Department of Cardiology and Heart Center, St Antonius Hospital, Nieuwegein, the Netherlands
Department of Cardiology, Maastricht University Medical Center (MUMC+) and CARIM School of Cardiovascular Diseases, Maastricht, the Netherlands
Search for more papers by this authorConstance Baaten
Department of Biochemistry, Maastricht University Medical Center (MUMC+) and CARIM School of Cardiovascular Diseases, Maastricht, the Netherlands
Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany
Search for more papers by this authorHugo ten Cate
Department of Biochemistry, Maastricht University Medical Center (MUMC+) and CARIM School of Cardiovascular Diseases, Maastricht, the Netherlands
Internal Medicine, Maastricht University Medical Center (MUMC+) and CARIM School of Cardiovascular Diseases, Maastricht, the Netherlands
Thrombosis Expertise Center, Maastricht University Medical Center (MUMC+) and CARIM School of cardiovascular diseases, Maastricht, the Netherlands
Center for Thrombosis and Haemostasis, Gutenberg University Medical Center, Mainz, Germany
Search for more papers by this authorWillem L Bor
Department of Cardiology and Heart Center, St Antonius Hospital, Nieuwegein, the Netherlands
Search for more papers by this authorDean RPP Chan Pin Yin
Department of Cardiology and Heart Center, St Antonius Hospital, Nieuwegein, the Netherlands
Search for more papers by this authorJurriën M ten Berg
Department of Cardiology and Heart Center, St Antonius Hospital, Nieuwegein, the Netherlands
Department of Cardiology, Maastricht University Medical Center (MUMC+) and CARIM School of Cardiovascular Diseases, Maastricht, the Netherlands
Search for more papers by this authorConstance Baaten
Department of Biochemistry, Maastricht University Medical Center (MUMC+) and CARIM School of Cardiovascular Diseases, Maastricht, the Netherlands
Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany
Search for more papers by this authorHugo ten Cate
Department of Biochemistry, Maastricht University Medical Center (MUMC+) and CARIM School of Cardiovascular Diseases, Maastricht, the Netherlands
Internal Medicine, Maastricht University Medical Center (MUMC+) and CARIM School of Cardiovascular Diseases, Maastricht, the Netherlands
Thrombosis Expertise Center, Maastricht University Medical Center (MUMC+) and CARIM School of cardiovascular diseases, Maastricht, the Netherlands
Center for Thrombosis and Haemostasis, Gutenberg University Medical Center, Mainz, Germany
Search for more papers by this authorAdam J Mead PhD, FRCP, FRCPath, FMedSci
Haematopoietic Stem Cell Biology Laboratory, Medical Research Council Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
Search for more papers by this authorMichael A Laffan DM, MRCP, FRCPath
Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK
Search for more papers by this authorGraham P Collins DPhil, FRCP, FRCPath
Department of Haematology, Oxford Cancer and Haematology Centre, Oxford, UK
Search for more papers by this authorDeborah Hay DPhil, MRCP, FRCPath
Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
Search for more papers by this authorA Victor Hoffbrand MA, DM, FRCP, FRCPath, FRCP (Edin), DSc, FMedSci
Emeritus Professor of Haematology Honorary Consultant Haematologist
University College London, London, UK
Royal Free Hospital, London, UK
Search for more papers by this authorSummary
Arterial thrombosis underlies cardiovascular diseases including myocardial infarction and ischaemic stroke. New insight in the pathophysiology of atherosclerosis and thrombosis stimulated the development of targeted antithrombotic medication. In this chapter, we discuss thrombus forming mechanisms, and indications for targeted antithrombotic medication in patients with atherothrombotic conditions and thromboembolic stroke.
Selected bibliography
- Angiolillo DJ , Bath DL , Cannon CP , et al . ( 2021 ) Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a north american perspective: 2021 update . Circulation 143 ( 6 ): 583 – 96 . doi: 10.1161/CIRCULATIONAHA.120.050438.
- Badimon L , Vilahur G ( 2014 ) Thrombosis formation on atherosclerotic lesions and plaque rupture . Journal of Internal Medicine 276 ( 6 ): 618 – 32 . doi: 10.1111/joim.12296 . Epub 2014 Sep 25. PMID: 25156650.
- Borissoff JI , Spronk HM , ten Cate H ( 2011 ) The hemostatic system as a modulator of atherosclerosis . The New England Journal of Medicine 364 ( 18 ): 1746 – 60 . doi: 10.1056/NEJMra1011670 . PMID: 21542745.
- Camm JA , Atar D ( 2021 ) Use of non-vitamin K antagonist oral anticoagulants for stroke prevention across stroke spectrum: progress and prospects . Thrombosis and Haemostasis 121 : 716 – 30 .
- Claassens DMF et al . ( 2019 ) A genotype-guided strategy for oral P2Y 12 inhibitors in primary PCI . New England Journal of Medicine 381 ( 17 ): 1621 – 31 . doi: 10.1056/nejmoa1907096.
- Collet JP , Thiele H , Barbato E , et al . ( 2021 ) 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation . European Heart Journal 42 ( 14 ): 1289 – 367 . doi: 10.1093/eurheartj/ehaa575.
- Dewilde WJM , Oirbans T , Verheugt FWA , et al . ( 2013 ) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial . The Lancet 381 ( 9872 ): 1107 – 15 . doi: 10.1016/S0140-6736(12)62177-1.
- Eikelboom JW , Connolly SW , Bosch J , et al . ( 2017 ) Rivaroxaban with or without aspirin in stable cardiovascular disease . New England Journal of Medicine 377 ( 14 ): 1319 – 30 . doi: 10.1056/NEJMoa1709118.
- Kumbhani DJ , Cannon CP , Beavers CJ , et al . ( 2021 ) 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of . Journal of the American College of Cardiology 77 ( 5 ): 629 – 58 . doi: 10.1016/j.jacc.2020.09.011.
- van der Meijden PEJ , Heemskerk JWM ( 2019 ) Platelet biology and functions: new concepts and clinical perspectives . Nature Reviews. Cardiology 16 ( 3 ): 166 – 179 . doi: 10.1038/s41569-018-0110-0 . PMID: 30429532.
- Nylander S , Schulz R ( 2016 ) Effects of P2Y12 receptor antagonists beyond platelet inhibition – comparison of ticagrelor with thienopyridines . British Journal of Pharmacology 173 ( 7 ): 1163 – 78 . doi: 10.1111/bph.13429 . Epub 2016 Feb 24. PMID: 26758983; PMCID: PMC5341337.
- Palmerini T , Della Riva D , Benedetto U , et al . ( 2017 ) Three, six, or twelve months of dual antiplatelet therapy after des implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients . European Heart Journal 38 ( 14 ): 1034 – 43 . doi: 10.1093/eurheartj/ehw627.
- Schüpke S , Neumann FJ , Menichelli M , et al . ( 2019 ) Ticagrelor or prasugrel in patients with acute coronary syndromes . New England Journal of Medicine 381 ( 16 ): 1524 – 34 . doi: 10.1056/nejmoa1908973.
- Sloane KL , Camargo EC ( 2019 ) Antithrombotic management of ischemic stroke . Current Treatment Options in Cardiovascular Medicine 21 ( 11 ): 78 . doi: 10.1007/s11936-019-0778-4 . PMID: 31792720.
-
Ten Cate H
,
Guzik TJ
,
Eikelboom
,
et al
. (
2020
)
Pleiotropic actions of factor Xa inhibition in cardiovascular prevention – mechanistic insights and implications for anti-thrombotic treatment
.
Cardiovascular Research
cvaa263
. doi:
10.1093/cvr/cvaa263
. Epub ahead of print. PMID: 32931586.
10.1093/cvr/cvaa263 Google Scholar
- Xiong Y , Bath PM ( 2020 ) Antiplatelet therapy for transient ischemic attack and minor stroke . Stroke 51 ( 11 ): 3472 – 4 . doi: 10.1161/STROKEAHA.120.031763 . Epub 2020 Sep 25. PMID: 32972314.
